Company
Headquarters: Shanghai, China
Employees: 2,127
CEO: Dr. Chen Cheney Mao
HK$1.28 Billion
HKD as of July 1, 2024
US$163.5 Million
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $121.36 B |
| Regeneron Pharmaceuticals, Inc. | $115.11 B |
| CSL Limited | $95.75 B |
| Marinomed Biotech AG | $75.67 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Viva Biotech Holdings, an investment holding company, provides structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides EFS, gene-to-protein and gene-to-structure, medicinal chemistry, in vitro pharmacology, membrane protein targeted drug discovery, and antibody discovery services, as well as Viva Engine, a platform for lead discovery. It also offers cell lines, crystal structures, GPCR proteins, antibodies, and proteins. In addition, the company provides contract development and manufacturing services for small molecule active pharmaceutical ingredients (APIs) and intermediates; and trades in APIs, intermediates, and formulations. Viva Biotech has a strategic collaboration agreement with BioMap Reach to jointly develop the early drug discovery through AI technology. Viva Biotech Holdings was incorporated in 2008 and is headquartered in Shanghai, China.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Viva Biotech Holdings has the following listings and related stock indices.
Stock: HKEX: 1873 wb_incandescent
Stock: FSX: VB0 wb_incandescent
Stock: OTC: VBIZF wb_incandescent